Optibrium Acquires StarDrop Software Platform for Guiding Decisions in Drug Discovery
7/21/2009 1:56:43 PM
Optibrium Limited is pleased to announce its acquisition of the StarDrop business from BioFocus DPI, a
subsidiary of Galapagos NV. StarDrop is a software platform, used by pharmaceutical and biotech companies
and research establishments globally, to guide compound selection and design decisions in drug discovery.
Optibrium, a company formed for the purpose of the acquisition by StarDrop’s management team, Dr Matt
Segall and Mr Ed Champness, is committed to building on the success of StarDrop by developing a next
generation of tools to guide decisions and optimise the drug discovery process.
Dr Matt Segall, CEO of Optibrium, said “The Optibrium team is excited by the opportunities this presents for
working with our existing customers, expanding our customer base and developing new products for the drug
Rob Arnold of Clasemont Limited, which acted as financial adviser to Optibrium, commented that “any deal is
tough to get away at the moment but there was a will on both sides for Matt and his team to achieve
independence as the best way to support StarDrop’s customers and to build for the future.”
Patrick Farrant of Taylor Vinters, which acted as Optibrium’s legal advisers, commented “The team was
delighted to work with Matt and Ed as they take StarDrop onto the next phase of its development."
Optibrium is dedicated to providing software to guide decisions involving complex, uncertain data in an
intuitive way. Our primary product, StarDrop, is focused on the drug discovery industry, helping scientists to
guide decisions in the design and selection of potential drug molecules.
Optibrium was founded in 2009 as a spin-out of BioFocus DPI (formerly Inpharmatica). The founding group was
responsible for the development of StarDrop from 2003 and, prior to this, research and development of
related technologies since 1994.
Based in Cambridge, UK, Optibrium has a global customer base ranging from top-10 pharmaceutical companies
to small biotechs and academic groups.
comments powered by